Search company, investor...

Pradama

pradama.com

Stage

Series B | Alive

Total Raised

$700K

Valuation

$0000 

Last Raised

$700K | 15 yrs ago

About Pradama

Pradama, Inc. is a pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders. Pradama is developing compounds that target bone with the initial two products designed for osteoporosis treatment and an antineoplastic compound for the treatment of bone metastases.

Headquarters Location

201 East Jefferson Street Suite 315

Louisville, Kentucky, 40202,

United States

502-852-7424

Missing: Pradama's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pradama's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Pradama

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pradama is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Pradama Frequently Asked Questions (FAQ)

  • Where is Pradama's headquarters?

    Pradama's headquarters is located at 201 East Jefferson Street, Louisville.

  • What is Pradama's latest funding round?

    Pradama's latest funding round is Series B.

  • How much did Pradama raise?

    Pradama raised a total of $700K.

  • Who are the investors of Pradama?

    Investors of Pradama include Triathlon Medical Venture Partners, Kentucky Seed Capital Fund and Commonwealth Seed Capital.

  • Who are Pradama's competitors?

    Competitors of Pradama include Humanetics, Tarsa Therapeutics, Auxilium Pharmaceuticals, Santarus, Aursos and 13 more.

Compare Pradama to Competitors

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Neurelis Logo
Neurelis

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

P
Phylogix

Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

R
ROXRO Pharma

Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.